A
Anders Sönnerborg
Researcher at Karolinska Institutet
Publications - 432
Citations - 21283
Anders Sönnerborg is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Viral load & Virus. The author has an hindex of 66, co-authored 407 publications receiving 19240 citations. Previous affiliations of Anders Sönnerborg include University of Missouri & University College London.
Papers
More filters
Journal ArticleDOI
HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics
Ana B. Abecasis,Annemarie M. J. Wensing,D Paraskevis,Jurgen Vercauteren,Jurgen Vercauteren,Kristof Theys,David A. M. C. van de Vijver,Jan Albert,Jan Albert,Birgitta Åsjö,Claudia Balotta,Danail Beshkov,Ricardo Jorge Camacho,Bonaventura Clotet,Cillian De Gascun,Algis Griskevicius,Zehava Grossman,Osamah Hamouda,Andrzej Horban,Tatjana Kolupajeva,Klaus Korn,Leon G. Kostrikis,Claudia Kücherer,Kirsi Liitsola,Marek Linka,Claus Nielsen,Dan Otelea,Roger Paredes,Mario Poljak,Elisabeth Puchhammer-Stöckl,Jean-Claude Schmit,Anders Sönnerborg,Danika Stanekova,Maja Stanojevic,Daniel Struck,Charles A. Boucher,Anne-Mieke Vandamme,Anne-Mieke Vandamme +37 more
TL;DR: The association of subtype with demographic parameters suggests highly compartmentalized epidemics, determined by social and behavioural characteristics of the patients, suggests they acquired their infection there or in Europe from compatriots.
Journal ArticleDOI
Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects.
TL;DR: It is concluded that efavirenz plasma concentration measurement gives reproducible results predictive of primary treatment failure, and a lower bound for the therapeutic level of 7 μmol/L is proposed, and data from other authors suggests that an upper level of 13 μ Mol/L may be applied.
Journal ArticleDOI
Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models
Mattia Prosperi,Mattia Prosperi,Michal Rosen-Zvi,Andre Altmann,Maurizio Zazzi,Simona Di Giambenedetto,Rolf Kaiser,Eugen Schülter,Daniel Struck,Peter M. A. Sloot,David A. M. C. van de Vijver,Anne-Mieke Vandamme,Anders Sönnerborg +12 more
TL;DR: Treatment history-based RF prediction models are comparable to GRT-based for classification of virological outcome and may be relevant for therapy optimisation in areas where availability of GRT is limited.
Journal ArticleDOI
Viral dynamics in primary HIV-1 infection
Stefan Lindbäck,Annika C. Karlsson,John E. Mittler,Anders Blaxhult,Mikael Carlsson,Gunnar Briheim,Anders Sönnerborg,Hans Gaines +7 more
TL;DR: PHI peak levels correlate with steady-state levels and HIV-1 RNA declines biphasically; an initial rapid decay is usually followed by a slow decay, which is similar to the initial changes seen with antiviral treatment.
Journal ArticleDOI
Impact of Therapeutic Immunization on HIV-1 Viremia after Discontinuation of Antiretroviral Therapy Initiated during Acute Infection
Sabine Kinloch-de Loes,Bruno Hoen,Don Smith,Brigitte Autran,Fiona C Lampe,Andrew N. Phillips,Li Ean Goh,Jan Andersson,Christos M. Tsoukas,Anders Sönnerborg,Giuseppe Tambussi,Pierre Marie Girard,Mark Bloch,Manuel Battegay,Nick Carter,Raphaelle El Habib,Georgia Theofan,David A. Cooper,Luc Perrin +18 more
TL;DR: Therapeutic immunization and ART, compared with ART alone, generated HIV-1-specific cellular immunity but did not lead to better virological control of HIV- 1 24 weeks after discontinuation of ART.